146 related articles for article (PubMed ID: 8529523)
1. Potassium channels in the cardiovascular system.
Pogátsa G
Diabetes Res Clin Pract; 1995 Aug; 28 Suppl():S91-8. PubMed ID: 8529523
[TBL] [Abstract][Full Text] [Related]
2. What kind of cardiovascular alterations could be influenced positively by oral antidiabetic agents?
Pogátsa G
Diabetes Res Clin Pract; 1996 Jul; 31 Suppl():S27-31. PubMed ID: 8864638
[TBL] [Abstract][Full Text] [Related]
3. Influence of hypoglycaemic sulphonylureas on the electrophysiological parameters of the heart.
Koltai MZ
Diabetes Res Clin Pract; 1996 Jul; 31 Suppl():S15-20. PubMed ID: 8864636
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular effects of sulphonylurea derivatives.
Smits P; Bijlstra PJ; Russel FG; Lutterman JA; Thien T
Diabetes Res Clin Pract; 1996 Jul; 31 Suppl():S55-9. PubMed ID: 8864641
[TBL] [Abstract][Full Text] [Related]
5. Sulphonylurea drugs no longer inhibit ATP-sensitive K+ channels during metabolic stress in cardiac muscle.
Findlay I
J Pharmacol Exp Ther; 1993 Jul; 266(1):456-67. PubMed ID: 8331572
[TBL] [Abstract][Full Text] [Related]
6. Interaction of sulphonylurea derivatives with vascular ATP-sensitive potassium channels in humans.
Bijlstra PJ; Lutterman JA; Russel FG; Thien T; Smits P
Diabetologia; 1996 Sep; 39(9):1083-90. PubMed ID: 8877293
[TBL] [Abstract][Full Text] [Related]
7. Haemodynamic and other effects of sulphonylurea drugs on the heart.
Végh A; Papp JG
Diabetes Res Clin Pract; 1996 Jul; 31 Suppl():S43-53. PubMed ID: 8864640
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular effects of conventional sulfonylureas and glimepiride.
Geisen K; Végh A; Krause E; Papp JG
Horm Metab Res; 1996 Sep; 28(9):496-507. PubMed ID: 8911987
[TBL] [Abstract][Full Text] [Related]
9. Adenosine triphosphate-sensitive potassium channel blocking agent ameliorates, but the opening agent aggravates, ischemia/reperfusion-induced injury. Heart function studies in nonfibrillating isolated hearts.
Tosaki A; Hellegouarch A
J Am Coll Cardiol; 1994 Feb; 23(2):487-96. PubMed ID: 8294705
[TBL] [Abstract][Full Text] [Related]
10. Haemodynamic and metabolic effects of low daily dose sulphonylureas in diabetic dog hearts.
Pósa I; Kocsis E; Nieszner E; Pogátsa G; Koltai MZ
Arzneimittelforschung; 2002; 52(7):552-9. PubMed ID: 12189779
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular effects of sulphonylurea derivatives. Implications for the treatment of NIDDM?
Smits P; Thien T
Diabetologia; 1995 Jan; 38(1):116-21. PubMed ID: 7744216
[TBL] [Abstract][Full Text] [Related]
12. The effects of the ATP-dependent potassium channel antagonist, glyburide, on coronary blood flow and susceptibility to ventricular fibrillation in unanesthetized dogs.
Billman GE; Avendano CE; Halliwill JR; Burroughs JM
J Cardiovasc Pharmacol; 1993 Feb; 21(2):197-204. PubMed ID: 7679152
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the efficacy of glibenclamide and glimepiride in reperfusion-induced arrhythmias in rats.
El-Reyani NE; Bozdogan O; Baczkó I; Leprán I; Papp JG
Eur J Pharmacol; 1999 Jan; 365(2-3):187-92. PubMed ID: 9988102
[TBL] [Abstract][Full Text] [Related]
14. Lithium chloride-induced cardiovascular changes in rabbits are mediated by adenosine triphosphate-sensitive potassium channels.
Abdel-Zaher AO; Abdel-Rahman MM
Pharmacol Res; 1999 Apr; 39(4):275-82. PubMed ID: 10208757
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular effects of sulphonylurea derivatives.
Smits P
Diabetologia; 1997 Jul; 40 Suppl 2():S160-1. PubMed ID: 9248730
[No Abstract] [Full Text] [Related]
16. Sulfonylurea derivatives in cardiovascular research and in cardiovascular patients.
Schotborgh CE; Wilde AA
Cardiovasc Res; 1997 Apr; 34(1):73-80. PubMed ID: 9217875
[TBL] [Abstract][Full Text] [Related]
17. Glimepiride (Hoe490) inhibits the rilmakalim induced decrease in intracellular free calcium and contraction of isolated heart muscle cells from guinea pigs to a lesser extent than glibenclamide.
Olbrich HG; Müller M; Lindner S; Henke B; Zarse M; Riehle M; Oremek G; Mutschler E
Int J Cardiol; 1999 Dec; 72(1):53-63. PubMed ID: 10636633
[TBL] [Abstract][Full Text] [Related]
18. [ATP-sensitive potassium channels and substances affecting them].
Pospísilová Y
Vnitr Lek; 1998 Jul; 44(7):435-8. PubMed ID: 9748883
[TBL] [Abstract][Full Text] [Related]
19. Effect of glimepiride and glibenclamide, inhibitors of ATP-dependent K(+)-channel, on ischaemia-reperfusion induced arrhythmias in rats.
Bozdogan O; Leprán I; Papp JG
Acta Physiol Hung; 1996; 84(3):265-6. PubMed ID: 9219599
[TBL] [Abstract][Full Text] [Related]
20. The antihypertensive and cardioprotective effects of (-)-MJ-451, an ATP-sensitive K(+) channel opener.
Lee YM; Yen MH; Peng YY; Sheu JR; Chen YC; Chang MJ; Cheng CY
Eur J Pharmacol; 2000 May; 397(1):151-60. PubMed ID: 10844109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
